Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2010

Parexel to Aid Lilly with Clinical Development in Asia-Pacific

  • Parexel established a strategic functional service provider relationship with Eli Lilly to support the latter’s clinical development programs in the Asia-Pacific region. Parexel will be in charge of starting up clinical trials and monitoring sites.

    Lilly expects the partnership to enable it to more effectively allocate studies and apply necessary resources to meet patient and portfolio needs. "Our strategic partnership with Parexel helps us focus on developing and maintaining relationships with investigators and regulators as core capabilities, while increasing our flexibility for managing monitoring resources to meet portfolio needs," notes Yukihito Kuwagaki, senior director of clinical development and medical science, Lilly Research Laboratories, Japan.

    Headquartered near Boston, MA, Parexel operates in 70 locations in 54 countries around the world and has approximately 9,720 employees. It provides a range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology, and medical-device industries. Perceptive Informatics, a subsidiary of Parexel, offers technology solutions including medical imaging to facilitate clinical development.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »